PUBLIC COMPANY
save$ERASErasca, Inc.
$ERAS17.32-4.12%San Diego, CA, USupdated 3h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase1A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
- phase2A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- phase3A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
- phase1A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
- phase1A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
- phase1A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- phase2A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
- phase1A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (3)
- Apr 1, 26option exerciseGarner Ebun · Chief Legal Officer80,000 sh
- Apr 1, 26option exerciseGarner Ebun · Chief Legal Officer80,000 sh
- Mar 4, 26option exerciseMorris Shannon · Chief Medical Officer20,000 sh
🐶 Hiring Signal
Where Erasca, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 11
News
- Erasca's $550M offering; Summit sells an antibioticPlus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public offering came after it shared a small ...endpoints · 1mo ago
- FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsTavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.biopharma_dive · 3mo ago
- STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapyThe drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer exceeded its expectations.stat · 3mo ago
- Erasca reports RAS cancer drug data after legal threat from RevolutionAfter a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown b…endpoints · 3mo ago
- Revolution Medicines threatens to sue Erasca over patent, efficacy claimsEarlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, Erasca said it had received a legal threat from Revolution Medicines' lawyers ove…endpoints · 3mo ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that